Acrivon Therapeutics, Inc. (ACRV) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-19

Key Insights

Acrivon Therapeutics announced plans to initiate arm 4 of the registrational intent ACR-368 phase 2b study, focusing on serous type endometrial cancer subjects with ≤2 prior lines of therapy. This suggests progress in the company's lead drug candidate development.
The company also completed exploratory arm 2 of the study, which treated biomarker-negative subjects with ≤3 prior lines of therapy using ACR-368 with ultra low dose gemcitabine (ULDG) sensitization. The study objectives were achieved, indicating ULDG may contribute to ACR-368 efficacy in biomarker-negative subjects with a favorable tolerability profile.
The updated corporate presentation provides investors with details on the company's pipeline progress and development strategy, which could be of interest to those tracking Acrivon's advancements.

Want the newest filings?

This analysis covers the filing from 2026-03-19. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-08

Acrivon Therapeutics reported positive interim data from the Phase 2b trial of its CHK1/CHK2 inhibitor ACR-368, showing a 39% ORR in monotherapy for biomarker-positive endometrial cancer patients and a 67% cORR in serous endometrial cancer patients.
The company has submitted a EU Clinical Trial Application to expand the ACR-368 Phase 2b trial into Europe, which is expected to accelerate enrollment and potentially allow for an earlier interim analysis.
Initial clinical data from the ongoing Phase 1 trial of Acrivon's WEE1/PKMYT1 inhibitor ACR-2316 has established favorable tolerability profiles for two weekly oral dosing regimens, providing dosing flexibility for potential future combinations.

Filed: 2026-01-08

Acrivon Therapeutics, a clinical-stage biopharmaceutical company, provided updates on its lead candidates ACR-368 and ACR-2316, including new clinical data.
The company hosted a corporate webcast and conference call to present the updates, which were also made available on the company's website.
The data update includes information on the progress of Acrivon's pipeline, indicating continued advancement of its programs.

Other reports for Acrivon Therapeutics, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.